Haemate (Human Von Willebrand Factor)

Haemate is indicated for the management of bleeding in patients with specific inherited clotting disorders.

• Replacement therapy for von Willebrand disease (type 1, 2, and 3).
• Adjunctive treatment to reduce bleeding during surgery or dental procedures in von Willebrand disease.
• Supportive therapy for hemophilia A patients with low factor VIII levels when von Willebrand factor is needed.
• Prophylactic use in patients with frequent spontaneous bleeds.
• Management of postpartum hemorrhage associated with von Willebrand factor deficiency.

Potential adverse reactions to Haemate have been reported; they vary in frequency and severity.

Common

• Headache, often mild and transient.
• Fever or chills occurring shortly after infusion.
• Nausea or vomiting, typically resolving without intervention.
• Local infusion site reactions such as erythema, swelling, or mild pain.

Serious

• Allergic reactions ranging from rash and urticaria to severe anaphylaxis.
• Thromboembolic events, including deep vein thrombosis or pulmonary embolism.
• Development of neutralizing antibodies (inhibitors) against von Willebrand factor.
• Renal dysfunction or hemolysis observed in rare cases.

Healthcare providers should consider several precautions when prescribing Haemate to ensure safe and effective use.

• Assess patient history for prior allergic reactions to plasma-derived products.
• Monitor for signs of thrombosis, especially in patients with risk factors.
• Evaluate renal and hepatic function before initiating therapy.
• Use caution in pregnant or breastfeeding women; limited safety data are available.
• Adjust dosing in patients with known inhibitors to von Willebrand factor.
• Avoid use in individuals with uncontrolled hypertension or active infection.

Haemate may interact with other medications; awareness of potential interactions helps minimize adverse outcomes.

Avoid

• Concomitant use of other plasma-derived clotting factor concentrates without medical supervision.
• High-dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.

Use with caution

• Antifibrinolytic agents (e.g., tranexamic acid) when combined may enhance clot stability.
• Warfarin or other anticoagulants, requiring close monitoring of coagulation parameters.
• Desmopressin (DDAVP) if used together, may increase von Willebrand factor levels excessively.